Charles River Laboratories International, Inc., CRL has seen numerous investment changes. Both Boston Trust Walden Corp and Bank of Nova Scotia made significant purchases of CRL stock while Allspring Global Investments Holdings LLC and Riverbridge Partners LLC reduced their holdings. These fluctuations come in spite of the stock hitting a 52-week high and being rated as a 'Moderate Buy' by analysts. The bio-tech giant's third-quarter 2025 earnings call highlighted strategic initiatives, securing the company a rating upgrade by both, Wall Street Zen and Bank of America. There have been concerns about CRL underperforming in comparison to the Dow, Nasdaq, and S&P 500. Changes in valuation and ownership focus were linked to fluctuations in stock price. CRL's strategic review involved divesting non-core assets with a focus on further commitment to their cell and gene therapy incubator program, and oncology partnerships expansion, signalling renewed strategic direction. Despite mixed reviews, the SEC concluded its investigation with no enforcement action, potentially lifting regulatory pressures from CRL.
Charles River Laboratories International CRL News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Wed, 31 Dec 2025 08:45:54 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -5
